New York State Common Retirement Fund Buys 25,849 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Common Retirement Fund increased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 41.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 87,516 shares of the company's stock after buying an additional 25,849 shares during the period. New York State Common Retirement Fund owned about 0.27% of TransMedics Group worth $6,908,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in TMDX. FMR LLC boosted its holdings in TransMedics Group by 42.5% in the third quarter. FMR LLC now owns 4,714,870 shares of the company's stock worth $258,139,000 after acquiring an additional 1,407,171 shares in the last quarter. Eventide Asset Management LLC lifted its stake in shares of TransMedics Group by 1,271.7% during the third quarter. Eventide Asset Management LLC now owns 925,356 shares of the company's stock worth $50,663,000 after buying an additional 857,895 shares during the period. Mackenzie Financial Corp purchased a new stake in shares of TransMedics Group during the fourth quarter valued at $35,804,000. Bank of New York Mellon Corp increased its position in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company's stock valued at $41,615,000 after acquiring an additional 363,012 shares during the period. Finally, American Century Companies Inc. lifted its position in TransMedics Group by 271.2% during the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company's stock worth $26,661,000 after acquiring an additional 355,755 shares during the period. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Trading Up 2.9 %

Shares of NASDAQ:TMDX traded up $3.55 during mid-day trading on Friday, reaching $127.99. 1,543,193 shares of the company were exchanged, compared to its average volume of 1,100,726. The firm has a market cap of $4.19 billion, a price-to-earnings ratio of -376.44 and a beta of 1.87. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $129.66. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The firm's 50-day simple moving average is $85.54 and its 200 day simple moving average is $77.08.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The business had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same quarter in the previous year, the firm earned ($0.08) EPS. The company's revenue was up 132.9% compared to the same quarter last year. Equities research analysts forecast that TransMedics Group, Inc. will post 0.54 EPS for the current year.

Insider Activity

In other news, insider Tamer I. Khayal sold 736 shares of the stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company's stock, valued at $1,295,043.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Tamer I. Khayal sold 736 shares of the business's stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total transaction of $66,306.24. Following the completion of the transaction, the insider now owns 14,375 shares in the company, valued at approximately $1,295,043.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward M. Basile sold 7,157 shares of the firm's stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $86.38, for a total value of $618,221.66. Following the completion of the sale, the director now owns 8,350 shares in the company, valued at $721,273. The disclosure for this sale can be found here. Insiders have sold 236,378 shares of company stock worth $23,633,449 over the last three months. 7.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on TMDX. Piper Sandler reiterated an "overweight" rating and issued a $120.00 target price (up previously from $95.00) on shares of TransMedics Group in a research report on Wednesday. JPMorgan Chase & Co. raised their target price on shares of TransMedics Group from $105.00 to $127.00 and gave the stock an "overweight" rating in a report on Wednesday. TD Cowen upped their price target on shares of TransMedics Group from $100.00 to $130.00 and gave the company a "buy" rating in a report on Wednesday. Canaccord Genuity Group boosted their price objective on TransMedics Group from $102.00 to $117.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Morgan Stanley upped their target price on TransMedics Group from $75.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $119.00.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.